Envestnet Asset Management
KPTI icon

Envestnet Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Envestnet Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-799
Closed -$72K – 3131
2019
Q2 		$72K Buy
799
+88
+12% +$7.07K ﹤0.01% 2974
2019
Q1 		$62K Buy
+711
New +$78.8K ﹤0.01% 2918
2017
Q1 		– Sell
-6
Closed -$1K – 3139
2016
Q4 		$1K Buy
+6
New +$811 ﹤0.01% 3039

Other funds holding KPTI

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Envestnet Asset Management's KPTI Position: Q3 2019 in Review

Envestnet Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2019, closing a stake of 799 shares — an estimated $72K sold.

Envestnet Asset Management first reported a position in KPTI in Q4 2016 and held it in 3 quarters. The position peaked at $72K in Q2 2019. 106 funds tracked by Wall St. Rank hold KPTI as of Q3 2019.

  • Envestnet Asset Management reported no remaining Karyopharm Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Envestnet Asset Management sold 799 Karyopharm Therapeutics shares in Q3 2019, an estimated $72K.
  • Envestnet Asset Management first reported a position in Karyopharm Therapeutics in Q4 2016 and held it in 3 quarters.
  • Envestnet Asset Management's Karyopharm Therapeutics position peaked at $72K in Q2 2019.
  • 106 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2019.

Based on Envestnet Asset Management's 13F filing for Q3 2019, filed 17 Oct 2019.